These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 7662198)

  • 1. Long-term zidovudine reduces neurocognitive deficits in HIV-1 infection.
    Baldeweg T; Catalan J; Lovett E; Gruzelier J; Riccio M; Hawkins D
    AIDS; 1995 Jun; 9(6):589-96. PubMed ID: 7662198
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Myopathies associated with human immunodeficiency virus and zidovudine: can their effects be distinguished?
    Simpson DM; Citak KA; Godfrey E; Godbold J; Wolfe DE
    Neurology; 1993 May; 43(5):971-6. PubMed ID: 8492955
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Zidovudine plus interferon-alpha versus zidovudine alone in HIV-infected symptomatic or asymptomatic persons with CD4+ cell counts > 150 x 10(6)/L: results of the Zidon trial. Zidon Study Group.
    Fernández-Cruz E; Lang JM; Frissen J; Furner V; Châteauvert M; Boucher CA; Dowd P; Stevens J
    AIDS; 1995 Sep; 9(9):1025-35. PubMed ID: 8527074
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The efficacy and safety of zidovudine alone or as cotherapy with acyclovir for the treatment of patients with AIDS and AIDS-related complex: a double-blind randomized trial. European-Australian Collaborative Group.
    Cooper DA; Pehrson PO; Pedersen C; Moroni M; Oksenhendler E; Rozenbaum W; Clumeck N; Faber V; Stille W; Hirschel B
    AIDS; 1993 Feb; 7(2):197-207. PubMed ID: 8096703
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A follow-up study of neuropsychological functioning in AIDS-patients. Prognostic significance and effect of zidovudine therapy.
    Karlsen NR; Reinvang I; Frøland SS
    Acta Neurol Scand; 1995 Mar; 91(3):215-21. PubMed ID: 7793239
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neurophysiological evaluation of zidovudine in asymptomatic HIV-1 infection: a longitudinal placebo-controlled study.
    Baldeweg T; Riccio M; Gruzelier J; Hawkins D; Burgess A; Irving G; Stygall J; Catt S; Catalan J
    J Neurol Sci; 1995 Oct; 132(2):162-9. PubMed ID: 8543942
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiretroviral effect and safety of abacavir alone and in combination with zidovudine in HIV-infected adults. Abacavir Phase 2 Clinical Team.
    Saag MS; Sonnerborg A; Torres RA; Lancaster D; Gazzard BG; Schooley RT; Romero C; Kelleher D; Spreen W; LaFon S
    AIDS; 1998 Nov; 12(16):F203-9. PubMed ID: 9833848
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changing incidence of HIV-induced brain lesions in Oslo, 1983-1994: effects of zidovudine treatment.
    Maehlen J; Dunlop O; Liestøl K; Dobloug JH; Goplen AK; Torvik A
    AIDS; 1995 Oct; 9(10):1165-9. PubMed ID: 8519453
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of antiviral therapy on the natural history of human immunodeficiency virus infection in a cohort of hemophiliacs.
    Ragni MV; Kingsley LA; Zhou SJ
    J Acquir Immune Defic Syndr (1988); 1992; 5(2):120-6. PubMed ID: 1732503
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Zidovudine adherence in persons with AIDS. The relation of patient beliefs about medication to self-termination of therapy.
    Smith MY; Rapkin BD; Morrison A; Kammerman S
    J Gen Intern Med; 1997 Apr; 12(4):216-23. PubMed ID: 9127225
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development and significance of zidovudine resistance in children infected with human immunodeficiency virus.
    Ogino MT; Dankner WM; Spector SA
    J Pediatr; 1993 Jul; 123(1):1-8. PubMed ID: 8100579
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Soluble tumor necrosis factor receptors as surrogate markers for the assessment of zidovudine treatment in asymptomatic HIV-1 infection.
    Godfried MH; van der Poll T; Mulder JW; Weverling GJ; Endert E; Lange JM; Sauerwein HP
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Dec; 10(5):531-9. PubMed ID: 8548332
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized study of combined zidovudine-lamivudine versus didanosine monotherapy in children with symptomatic therapy-naive HIV-1 infection. The Pediatric AIDS Clinical Trials Group Protocol 300 Study Team.
    McKinney RE; Johnson GM; Stanley K; Yong FH; Keller A; O'Donnell KJ; Brouwers P; Mitchell WG; Yogev R; Wara DW; Wiznia A; Mofenson L; McNamara J; Spector SA
    J Pediatr; 1998 Oct; 133(4):500-8. PubMed ID: 9787687
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rate of CD4 cell decline and prediction of survival in zidovudine-treated patients.
    Easterbrook PJ; Emami J; Gazzard B
    AIDS; 1993 Oct; 7(10):959-67. PubMed ID: 7903542
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of zidovudine in 30 patients with mild to end-stage AIDS dementia complex.
    Tozzi V; Narciso P; Galgani S; Sette P; Balestra P; Gerace C; Pau FM; Pigorini F; Volpini V; Camporiondo MP
    AIDS; 1993 May; 7(5):683-92. PubMed ID: 8318176
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High incidence of zidovudine induced anaemia in HIV infected patients in eastern India.
    Agarwal D; Chakravarty J; Chaube L; Rai M; Agrawal NR; Sundar S
    Indian J Med Res; 2010 Oct; 132():386-9. PubMed ID: 20966515
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peripheral nerve function in persons with asymptomatic or minimally symptomatic HIV disease: absence of zidovudine neurotoxicity.
    Bozzette SA; Santangelo J; Villasana D; Fraser A; Wright B; Jacobsen C; Hayden E; Schnack J; Spector SA; Richman DD
    J Acquir Immune Defic Syndr (1988); 1991; 4(9):851-5. PubMed ID: 1654410
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reductions in HIV-1 disease progression for zidovudine/lamivudine relative to control treatments: a meta-analysis of controlled trials.
    Staszewski S; Hill AM; Bartlett J; Eron JJ; Katlama C; Johnson J; Sawyer W; McDade H
    AIDS; 1997 Mar; 11(4):477-83. PubMed ID: 9084795
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nevirapine and zidovudine at birth to reduce perinatal transmission of HIV in an African setting: a randomized controlled trial.
    Taha TE; Kumwenda NI; Hoover DR; Fiscus SA; Kafulafula G; Nkhoma C; Nour S; Chen S; Liomba G; Miotti PG; Broadhead RL
    JAMA; 2004 Jul; 292(2):202-9. PubMed ID: 15249569
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Longitudinal study on the Quality of Life of symptomatic HIV-infected patients in a trial of zidovudine versus zidovudine and interferon-alpha.
    de Boer JB; van Dam FS; Sprangers MA; Frissen PH; Lange JM
    AIDS; 1993 Jul; 7(7):947-53. PubMed ID: 8357556
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.